ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation

Sanofi’s Sarclisa has had difficulty competing with Johnson & Johnson’s Darzalex, largely because it reached the market five years later. But one advancement that could help Sanofi close some of the gap is its on-body delivery system for its CD38 antibody.

Jun 3, 2025 - 13:35
 0
ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation
Sanofi’s Sarclisa has had difficulty competing with Johnson & Johnson’s Darzalex, largely because it reached the market five years later. But one advancement that could help Sanofi close some of the gap is its on-body delivery system for its CD38 antibody.